Stocks Health care CGTX
NASDAQ · Health careCognition Therapeutics Inc (CGTX)
It posted a net loss of $16.8M. At June 30, 2026 it held $34M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Cognition Therapeutics Inc
- Net worth
- Cognition Therapeutics Inc has a market value (market cap) of $65.7M at the latest share price, and shareholders' equity of $33M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $24.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cognition Therapeutics Inc's next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Cognition Therapeutics Inc does
Cognition Therapeutics Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$23.5M | -$0.32 | n/a |
| 2024 | n/a | -$34M | -$0.86 | -$28.5M |
| 2023 | n/a | -$25.8M | -$0.86 | -$16.2M |
| 2022 | n/a | -$21.4M | -$0.91 | -$18.7M |
| 2021 | n/a | -$11.7M | -$3.13 | -$3.7M |
| 2021 | n/a | -$7.8M | -$23.76 | -$3.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cognition Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026
- August 6, 2026
- June 24, 2026Other event 8-K
- June 18, 2026
- June 4, 2026
- May 21, 2026Other event 8-K
- May 8, 2026
- May 7, 2026
- April 27, 2026
- April 27, 2026Additional proxy material DEFA14A
Insider trades
What the people running Cognition Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 17, 2026 | Richstone Ellen BDirector | Received as pay | 25,000 | - |
| June 17, 2026 | Wallace PeggyDirector | Received as pay | 25,000 | - |
| June 17, 2026 | Monia Brett PDirector | Received as pay | 25,000 | - |
| June 17, 2026 | Khattar Jack A.Director | Received as pay | 25,000 | - |
| June 17, 2026 | Fletcher Aaron G.L.Director, 10% owner | Received as pay | 25,000 | - |
| May 1, 2026 | Doyle John BrendanChief Financial Officer | Shares withheld for tax | 8,567 | $11K |
| April 16, 2026 | Caggiano AnthonyChief Medical Officer | Bought | 10,000 | $11.1K |
| April 16, 2026 | Ricciardi LisaCEO & President, Director | Bought | 9,175 | $10.1K |
Who owns CGTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bios Capital Management, LP13D, may seek influence with 21 related filers | 19.4% | November 13, 2023 |
| Aaron G.L. Fletcher13D, may seek influence with 21 related filers | 6.9% | September 23, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 66 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BIOS Capital Management, LP | 6,000,000 | 0 |
| DAVENPORT & Co LLC | 4,259,511 | +1,366,703 |
| Vanguard Capital Management LLC | 3,438,775 | +436,988 |
| BlackRock, Inc. | 1,261,993 | +293,631 |
| Chescapmanager LLC | 997,029 | 0 |
| Geode Capital Management, LLC | 910,006 | -10,202 |
| Renaissance Technologies LLC | 693,288 | -423,848 |
| Hilton Capital Management, LLC | 548,950 | 0 |
| Vanguard Fiduciary Trust Co | 508,220 | +44,536 |
| CM Management, LLC | 450,000 | +50,000 |
| Dauntless Investment Group, LLC | 371,701 | -59,299 |
| Sigma Planning Corp | 362,265 | +24,500 |
| State Street Corp | 348,983 | +34,500 |
| Tocqueville Asset Management L.P. | 320,500 | +125,500 |
| UBS Group AG | 218,536 | +141,663 |
| American Financial Group Inc | 205,000 | 0 |
| Northern Trust Corp | 178,202 | +9,516 |
| Voss Capital, LP | 175,000 | -25,000 |
| Texas Capital Bank Wealth Management Services Inc | 143,296 | +20,000 |
| Charles Schwab Investment Management Inc | 84,940 | 0 |
Insiders
8 insiders reported holding 3,632,889 shares in total, about $2.5M at the last price.
| Holder | Shares |
|---|---|
| Ricciardi LisaCEO & President, Director | 1,715,851 |
| Caggiano AnthonyChief Medical Officer | 874,906 |
| Doyle John BrendanChief Financial Officer | 618,942 |
| Wallace PeggyDirector | 111,461 |
| Richstone Ellen BDirector | 83,500 |
| Fletcher Aaron G.L.Director, 10% owner | 81,229 |
| Khattar Jack A.Director | 73,500 |
| Monia Brett PDirector | 73,500 |
Questions about CGTX
What does Cognition Therapeutics Inc do?
Cognition Therapeutics Inc is a company in the Health care sector, listed on NASDAQ as CGTX. Its shares trade on NASDAQ under the ticker CGTX.
What is Cognition Therapeutics Inc's net worth?
Cognition Therapeutics Inc has a market value (market cap) of $65.7M at the latest share price, and shareholders' equity of $33M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cognition Therapeutics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $16.8M.
When did Cognition Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026.
When is Cognition Therapeutics Inc's next earnings report?
Cognition Therapeutics Inc's next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare CGTX with
Follow CGTX
Get an email when Cognition Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cognition Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.